Keywords
Receptors
T lymphocytes
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To explore and analyze the latest advances in CAR-T therapy, highlighting its clinical applications and strategies to reduce adverse reactions. Literature review: CAR-T therapy is based on fusion protein receptors, chimeric antigen receptors (CARs), designed to direct T lymphocytes to antigens expressed on cancer cells and in autoimmune disorders. Currently, it represents a significant breakthrough in the oncological field, particularly for the treatment of hematologic malignancies such as leukemias and lymphomas. However, recent studies are already exploring the expansion of this treatment modality to autoimmune diseases and solid tumors, necessitating advancements in genetic engineering to ensure the safety of these interventions. One of the primary challenges in using this therapy is the need to mitigate potential severe side effects, particularly cytokine release syndrome and neurotoxicity. Final considerations: Investigating and understanding CAR-T cell therapy is crucial, as this approach has shown promising response rates and survival, especially in patients with hematologic tumors. Therefore, this therapy offers new hope for those who do not respond to conventional treatments such as chemotherapy and radiotherapy.
References
ADKINS S. CAR T. Cell Therapy: Adverse Events and Management. Journal of the advanced practitioner in oncology, 2019; 10(3): 21–28.
BOARDMAN A e SALLES G. CAR T‐cell therapy in large B cell lymphoma. Hematological oncology, 2023; 41(1): 112–118.
CAPPELL KM e KOCHENDERFER JN.Resultados de longo prazo após terapia com células T CAR: o que sabemos até agora. Nature reviews. Clinical oncology,2023; 20(6): 359–371.
CHOW VA, et al. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood, 2018;132(8): 777–781.
FISCHER BN. cell therapy: Mechanism, management, and mitigation of inflammatory toxicities. Frontiers in immunology, 2021;12: 693016.
GUZMAN G, et al. CAR‑T Therapies in Solid Tumors: Opportunities and Challenges. Current Oncology Reports, 2023; 25: 479–489.
HOPFINGER G, et al. CAR-T cell therapy in diffuse large B cell lymphoma: Hype and hope. HemaSphere, 2019; 3(2): 185.
HU B, et al. Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas. Frontiers in oncology, 2024; 14: 1394057.
HUNTER BD e JACOBSON CA. CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions. Journal of the National Cancer Institute, 2019; 111(7): 646–654.
JOGALEKAR MP, et al. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments, 2022; 10: 3389.
LEE DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet, 2015; 385(996): 517–528.
MUNSHI PN e UJJANI C. The acceleration of CAR-T therapy in non-Hodgkin lymphoma. Hematological oncology, 2019; 37(3): 233–239.
MAUDE SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England journal of medicine, 2014; 371 (16): 1507–1517.
MAUDE SL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015; 125(26): 4017-23.
OLUWOLE OO, et al. Navegando pelos desafios: Gestão eficaz de toxicidades em terapias com células T CAR. Journal of the National Comprehensive Cancer Network: JNCCN, 2023; 21: 6–8.
PARK JH, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. The New England journal of medicine, 2018; 378 (5): 449–459.
RIET T e CHMIELEWSKI M. Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges. Frontiers in immunology, 2022; 13: 934343.
SERMER D e BRENTJENS R. CAR T-cell therapy: Full speed ahead. Hematological oncology, 2019; 37(1): 95–100.
SOARES JEP, et al. Terapia com células CAR-T: reprogramação celular para combater neoplasias malignas. Revista Médica de Minas Gerais, 2022; 32.
SOUZA KS, et al. Imunoterapia dirigida com células T-CAR para tratamento de leucemia linfóide aguda. Research, Society and Development, 2020; 9(11): 72891110372.
STERNER RC e STERNER RM. CAR-T cell therapy: current limitations and potential strategies. Blood cancer journal, 2021; 11(4): 69.
TRABOLSI A, et al. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood cancer journal, 2024; 14(1): 27.
YU H, et al. CART cell therapy for prostate cancer: status and promise. OncoTargets and therapy, 2019; 12:391–395.
WANG Z, et al. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein Cell, 2017; 8(12): 896-925.
ZHANG S. Current clinical outcome of CD19/CD22 dual-targeting CAR T-cell therapy in refractory or relapsed B-cell acute lymphoblastic leukemia. Highlights in Science, Engineering and Technology, 2023; 54: 264–279.
ZHANG BL, et al. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Science China Life Sciences, 2016; 59(4): 340–348.